[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Climb Bio Inc (CLYM)

Climb Bio Inc (CLYM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 543,134
  • Shares Outstanding, K 47,769
  • Annual Sales, $ 0 K
  • Annual Income, $ -59,850 K
  • EBIT $ -68 M
  • EBITDA $ -70 M
  • 60-Month Beta 0.02
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.55

Options Overview Details

View History
  • Implied Volatility 173.28% (-3.97%)
  • Historical Volatility 80.11%
  • IV Percentile 10%
  • IV Rank 7.38%
  • IV High 728.63% on 02/05/26
  • IV Low 129.02% on 05/06/26
  • Expected Move (DTE 4) 0.35 (2.89%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 2
  • Volume Avg (30-Day) 166
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 3,132
  • Open Int (30-Day) 1,939
  • Expected Range 11.71 to 12.41

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.25
  • Number of Estimates 8
  • High Estimate $-0.18
  • Low Estimate $-0.31
  • Prior Year $-0.13
  • Growth Rate Est. (year over year) -92.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.91 +48.55%
on 05/01/26
12.48 -5.85%
on 05/11/26
+3.34 (+39.71%)
since 04/10/26
3-Month
5.06 +132.41%
on 02/12/26
12.48 -5.85%
on 05/11/26
+6.19 (+111.33%)
since 02/11/26
52-Week
1.13 +939.82%
on 05/15/25
12.48 -5.85%
on 05/11/26
+10.56 (+887.39%)
since 05/09/25

Most Recent Stories

More News
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at...

CLYM : 11.77 (+3.52%)
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; Fast...

CLYM : 11.77 (+3.52%)
Climb Bio, Inc. Announces $110.0 Million Private Placement

WELLESLEY HILLS, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...

CLYM : 11.77 (+3.52%)
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026

WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...

CLYM : 11.77 (+3.52%)
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy

WELLESLEY HILLS, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today...

CLYM : 11.77 (+3.52%)
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates 

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials...

CLYM : 11.77 (+3.52%)
Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY HILLS, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today...

CLYM : 11.77 (+3.52%)
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026

First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026  Dosing ongoing in budoprutug Phase 1b/2a trial in ITP and Phase 1b trial in SLE; achieved...

CLYM : 11.77 (+3.52%)
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today...

CLYM : 11.77 (+3.52%)
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates

PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated  Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical...

CLYM : 11.77 (+3.52%)

Business Summary

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell...

See More

Key Turning Points

3rd Resistance Point 12.89
2nd Resistance Point 12.56
1st Resistance Point 11.97
Last Price 11.77
1st Support Level 11.05
2nd Support Level 10.72
3rd Support Level 10.13

See More

52-Week High 12.48
Last Price 11.77
Fibonacci 61.8% 8.14
Fibonacci 50% 6.80
Fibonacci 38.2% 5.47
52-Week Low 1.13

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.